AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Oct 09, 2019

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress

NORTH CHICAGO, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult patients with moderate to severe plaque psoriasis, as well as additional data on HUMIRA® (adalimumab) and the investigational JAK inhibitor upadacitinib, at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, in Madrid.

Oct 08, 2019

AbbVie to Host Third-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., Oct. 8, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its third-quarter 2019 financial results on Friday, November 1 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Sep 27, 2019

AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE: AGN) have each received a Request for Additional Information (Second Request) from the Federal Trade Commission (FTC) in connection with AbbVie's pending acquisition of Allergan.

Sep 26, 2019

AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of MAVYRET® (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6). In August 2017, MAVYRET received regulatory approval in the U.S. as an 8-week, pan-genotypic treatment for treatment-naïve HCV patients without cirrhosis.

Sep 25, 2019

AbbVie Announces Public Voting Open for the 2019 AbbVie CF Scholarship Thriving Student Awards, Given to Two Exceptional Students Living with Cystic Fibrosis

NORTH CHICAGO, Ill., Sept. 25, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced the start of its public voting period for the 2019 Thriving Undergraduate and Thriving Graduate Scholarship. Following this voting period, scholarships totaling $25,000 each will be given to two commendable students living with cystic fibrosis (CF), an inherited chronic disease that affects the lungs and digestive system.

Sep 23, 2019

AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®

NORTH CHICAGO, Ill., Sept. 23, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present results from two late-breaking abstracts, including final data from the Phase 1b study evaluating the safety and tolerability of the investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD), and data from the real-world DUOGLOBE study, evaluating the effect of DUODOPA® (levodopa/carbidopa intestinal gel) in patients with advanced Parkinson's disease. In total, 22 abstracts featuring new and updated data evaluating AbbVie's neuroscience portfolio and pipeline will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders®, September 22-26 in Nice, France.

Sep 06, 2019

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Sept. 6, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share. 

Aug 29, 2019

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program

NORTH CHICAGO, Ill., Aug. 29, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research based global biopharmaceutical company, today announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a pre-planned interim analysis for patients receiving Rova-T as compared with placebo. The overall safety profile was generally consistent with that observed in previous studies. The MERU trial is being closed, and the Rova-T research and development program has been terminated. AbbVie will move forward prioritizing other development programs within its oncology pipeline.

Aug 27, 2019

AbbVie to Present at the Morgan Stanley Healthcare Conference

NORTH CHICAGO, Ill., Aug. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019.  Richard A. Gonzalez, chairman and chief executive officer, will present at 10:10 a.m. Central time.

Aug 16, 2019

AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis

NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).1 RINVOQ is expected to be available in the U.S. in late August 2019.